Hints and tips:
Related Special Reports
...In the following years, Genzyme would bring out medicines for other rare diseases such as Pompe....
...Sanofi has gambled before and won; the $20bn acquisition of Genzyme in 2011 was pricey and unpopular at the time, but few are complaining now....
...Once example is Genzyme, which was bought by Sanofi in 2011....
...He says only one company — Genzyme, a unit of French pharmaceuticals giant Sanofi — makes the enzyme replacer that Ximena needs. Her treatment costs the Mexican state $7,700 every week....
...David Meeker, head of the Genzyme specialty care business, a Sanofi subsidiary, said last month that rare disease assets were among the potential targets for the company as it eyes growth opportunities....
...Mr Brandicourt has moved to deepen integration of Genzyme into the parent group, renaming it Sanofi Genzyme and giving it responsibility for all of Sanofi’s speciality medicines....
...But over the summer chief executive Christopher Viehbacher said he wanted to move to Boston, where Genzyme is based....
...But the move symbolises the growing importance of Massachusetts, where Genzyme is based, to Sanofi’s fortunes....
...Boston has become an important centre for the company since its $20bn acquisition of Genzyme, the Massachusetts-based biotech company, in 2011....
...In contrast Sanofi noted sales at Genzyme, its rival rare disease subsidiary, were up a quarter to €493m....
...Yet Sanofi’s purchase of Genzyme in 2011 did not spark large-scale consolidation. Deals are centred on smaller companies such as Elan and Life Technologies....
...Royalty’s use of a contingent value right – a growing trend in conditional payments employed by others including Sanofi in its takeover of Genzyme – allows it to pay more based on the scale of future Tysabri...
...So, too, did last year’s purchase of Genzyme, the US biotech company that specialises in rare disease medicines. At more than $20bn, it was a bold acquisition....
...Big pharma understands this trend – consider Sanofi’s acquisition of Genzyme last year – but must continue to adopt research programmes, acquisition strategies and sales forces to the new reality....
...Angus Russell, Shire’s chief executive, told the Financial Times last month he was confident of retaining market share won from Genzyme....
...He expressed confidence that Shire would be able to retain the market share gains on treatments for the rare Fabry’s and Gaucher’s diseases that it gained from its rival Genzyme, which suffered shortfalls...
...Genzyme’s production plants, however, should be back online in 2012. If it were to discount prices to win back share, Shire would find itself in a price war....
...Since 2009, Shire had supplied Replagal to US patients for free in response to manufacturing problems at Genzyme, which produced the only direct competitor....
...However, there are a number of examples of companies which have bought into growth through acquisition of higher tech businesses – Sanofi buying Genzyme, for example, or Roche buying Genentech....
...Chris Viehbacher, chief executive, said: “The big news is we have consolidated Genzyme for the first time. Despite losses to generics, our growth platforms continue to roll along....
...€2.5bn in the third quarter last year, after a growth in costs offset a 5 per cent rise in sales to €8.8bn linked to emerging markets, strong performance from its diabetes products and extra revenues from Genzyme...
...Mr Viehbacher said Sanofi had the potential for “near-term bolt-on acquisitions” valued at €1bn-€2bn, and highlighted double-digit growth from emerging markets and Genzyme as well as strong growth from consumer...
...Most subsequent deals have been more targeted on particular products or regions, such as Sanofi’s purchase of Genzyme in 2011, which specialises in “orphan diseases”; Johnson & Johnson’s purchase of Synthes...
International Edition